Sophiris Will Start Phase III For Topsalysin In Prostate Cancer Despite Mixed Data Package
Executive Summary
Emphasizing solid results for the first administration of topsalysin in patients with localized prostate cancer, the firm is sticking with Phase III plans for one dose despite final Phase IIb data showing no clinical benefit from a second dose. Sophiris’ share price tumbled on the news.